Medicine and Dentistry
Adverse Event
7%
Alanine Aminotransferase
11%
Alcohol Consumption
19%
Alcohol Liver Cirrhosis
35%
Alcohol Liver Disease
84%
Alcoholic Polyneuropathy
7%
Bariatric Surgery
7%
Bilirubin
5%
Cardiovascular Disease
12%
Chronic Kidney Disease
7%
Chronic Liver Disease
12%
Clinical Predictor
28%
Cohort Analysis
5%
COVID-19
56%
Daclatasvir
28%
Discriminant Analysis
5%
Disease
12%
Endocrine Disease
5%
Granulocyte Colony Stimulating Factor
28%
Hazard Ratio
5%
Health System
30%
Hepatitis A
56%
Immunosuppressive Treatment
7%
Infection
9%
Injury
20%
Karnofsky Performance Status
6%
Kidney Disorder
7%
Liver Cirrhosis
9%
Liver Disease
100%
Liver Failure
9%
Liver Function Test
30%
Liver Graft
67%
Liver Injury
30%
Malignant Neoplasm
14%
Model For End Stage Liver Disease Score
32%
Model for End-Stage Liver Disease
39%
Mortality Rate
11%
Nonalcoholic Fatty Liver
28%
Odds Ratio
8%
Patient Population
7%
Physical Disease by Body Function
7%
Post-COVID-19
28%
Preoperative Evaluation
11%
Renal Replacement Therapy
28%
Reoperation
6%
Retrospective Study
5%
Sarcopenic Obesity
7%
Steatosis
10%
Surgical Risk
7%
Therapeutic Window
28%
Keyphrases
Alcohol
9%
Alcohol Consumption
9%
Alcohol Relapse
7%
Alcohol Use Disorder
14%
Alcohol-related
9%
Alcoholic Cirrhosis
9%
Alcoholic Liver Disease
28%
Anatomical Constraints
14%
Bariatric Surgery
14%
Cardiovascular Risk
14%
Chronic Liver Disease
14%
Comorbidity
14%
Complications of Liver Transplantation
14%
Covert Hepatic Encephalopathy
28%
Daclatasvir
28%
Direct-acting Antivirals
28%
Disease Entity
9%
Excessive Drinking
9%
Extrahepatic Complications
28%
Growing Patients
14%
Health Problems
9%
Hepatitis C Virus Replication
14%
Immunosuppressive Therapy
14%
Liver Disease
23%
Liver Failure
14%
Liver Transplant Evaluation
14%
Liver Transplant Recipients
28%
Livery
24%
Mechanism of Action
14%
Metabolic Dysfunction
28%
Metabolic Health
28%
Metabolic Obesity
28%
Metabolic Risk Factors
28%
Metabolic-associated Fatty Liver Disease (MAFLD)
14%
Non-absorbable Disaccharides
5%
Operative
14%
Pathologic Processes
9%
Patient Demographics
14%
Post-COVID-19 Pandemic
28%
Post-liver Transplant
14%
Potential Adverse Effects
9%
Preoperative Risk Assessment
14%
Public Knowledge
9%
Renal Disease
14%
Sarcopenic Obesity
14%
Severe Alcoholic Hepatitis
9%
Simple Steatosis
9%
Socioeconomic Issues
9%
Strict Control
14%
World Health Organization
9%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
7%
Alanine Aminotransferase
8%
Alcohol Liver Cirrhosis
35%
Alcohol Liver Disease
84%
Cardiovascular Disease
5%
Chronic Kidney Failure
7%
Cohort Study
5%
Colorectal Cancer
5%
Daclatasvir
28%
Diabetes Mellitus
5%
Disease
11%
End Stage Liver Disease
59%
Endocrine Disease
5%
Ethanol
95%
Granulocyte Colony Stimulating Factor
28%
Hepatitis A
56%
Infection
6%
Injury
20%
Liver Cirrhosis
7%
Liver Disease
52%
Liver Injury
28%
Metabolic Syndrome X
5%
Mortality Rate
11%
Nonalcoholic Fatty Liver
28%
Physical Disease by Body Function
7%
Replacement Therapy
28%
Retrospective Study
5%
Steatosis
10%
Therapeutic Window
28%